Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In mammalian cells, the
p38 mitogen-activated protein kinase
(
MAPK
) pathway is activated in response to a variety of environmental stresses and inflammatory stimuli. However, the role of p38
MAPK
signaling in unchallenged conditions remains largely unknown. We have isolated mutations in a Drosophila p38 MAPKK gene homolog, licorne (lic), and show that during oogenesis, lic is required in the germ line for correct asymmetric development of the egg. In lic mutant egg chambers, oskar mRNA posterior localization is not properly maintained, resulting in anteroposterior patterning defects in the embryo. Furthermore, lic loss-of-function in the germ line leads to reduced EGF receptor activity in dorsal follicle cells and ventralization of the egg shell. Both these defects are associated with a diminution of gurken protein levels in the oocyte. Our phenotypic data argue for a role of lic in a post-transcriptional regulation of the grk gene. Furthermore, they show that in addition to the well-characterized Ras/Raf/ERK
MAPK
pathway acting in the follicle cells, another related signaling cascade, the p38
MAPK
pathway, is required in the germ line for correct axes determination. These results provide the first genetic demonstration of an essential function for a p38 pathway during development.
...
PMID:The Drosophila p38 MAPK pathway is required during oogenesis for egg asymmetric development. 1036 62
Basic fibroblast growth factor (FGF-2) is a member of a family of polypeptides that have roles in a wide range of biological processes. To determine why different cell types show distinct responses to treatment with FGF-2, the array of FGF receptors present on the surface of a cell which differentiates in response to FGF-2 (PC12 cells) was compared with that present on the surface of a cell that proliferates in response to FGF-2 (Swiss 3T3 fibroblasts). Both cell types express exclusively FGFR1, suggesting that there are cell type-specific FGFR1 signaling pathways. Since mitogen-activated protein kinases function as mediators of cellular responses to a variety of stimuli, the roles of these proteins in FGF-mediated responses were examined. FGF-2 activates extracellular signal-regulated kinases with similar kinetics in both fibroblasts and PC12 cells, and a specific inhibitor of
extracellular signal-regulated kinase
activation blocks differentiation but has little effect on proliferation. In contrast, while
p38 mitogen-activated protein kinase
is activated weakly and transiently in PC12 cells treated with FGF-2, a much stronger and sustained activation of this kinase is seen in FGF-2-treated fibroblasts. Furthermore, specific inhibitors of this kinase block proliferation but have no effect on differentiation. This effect on proliferation is specific for FGF-2 since the same concentrations of inhibitors have little or no effect on proliferation induced by serum.
...
PMID:p38 mitogen-activated protein kinase activation is required for fibroblast growth factor-2-stimulated cell proliferation but not differentiation. 1036 80
This study investigates whether the guanine nucleotide exchange activity of Vav is linked to cytokine production in mast cells. Overexpression of Vav in the RBL-2H3 mast cell line resulted in the constitutive tyrosine phosphorylation and activation of Vav. We analyzed the functional effect of Vav overexpression on cytokine production. IL-2 and IL-6 mRNA levels were dramatically increased in Vav-overexpressing cells and correlated with increased NF-AT activity. Little or no effect was observed on the mRNA levels of IL-3, IL-4, GM-CSF, TNF-alpha, and TGF-beta. FcepsilonRI engagement did not further enhance IL-2 and IL-6 mRNA levels and only slightly enhanced NF-AT activity, but dramatically increased the mRNA levels of other tested cytokines. To understand the signal transduction required, we focused primarily on IL-6 induction by measuring
mitogen-activated protein kinase
activity and analyzing the effects of mutant or dominant negative forms of Vav, Rac1, and
c-Jun N-terminal kinase
-1 (JNK1). Vav overexpression resulted in the constitutive activation of JNK1 with little or no effect on
p38 mitogen-activated protein kinase
and
ERK2
. This was dependent on Vav-mediated activation of Rac1 as a Dbl domain-mutated Vav, inactive Rac N17, and inactive JNK1 down-regulated the Vav-induced JNK1 or IL-6 responses. Vav expression, but not expression of domain-mutated Vav, increased IL-6 secretion from nonimmortalized bone marrow-derived mast cells upon FcepsilonRI engagement. We conclude that Vav phosphorylation contributes to IL-6 induction in mast cells.
...
PMID:Tyrosine phosphorylation of Vav stimulates IL-6 production in mast cells by a Rac/c-Jun N-terminal kinase-dependent pathway. 1039 73
Leukocyte protein tyrosine phosphatase (LC-PTP)/hemopoietic PTP is a human cytoplasmic PTP that is predominantly expressed in the hemopoietic cells. Recently, it was reported that hemopoietic PTP inhibited TCR-mediated signal transduction. However, the precise mechanism of the inhibition was not identified. Here we report that
extracellular signal-regulated kinase
(
ERK
) is the direct target of LC-PTP. LC-PTP dephosphorylated
ERK2
in vitro. Expression of wild-type LC-PTP in 293T cells suppressed the phosphorylation of
ERK2
by a mutant MEK1, which was constitutively active regardless of upstream activation signals. No suppression of the phosphorylation was observed by LC-PTPCS, a catalytically inactive mutant. In Jurkat cells, LC-PTP suppressed the
ERK
and
p38 mitogen-activated protein kinase
cascades. LC-PTP and LC-PTPCS made complexes with
ERK1
,
ERK2
, and p38alpha, but not with the gain-of-function sevenmaker
ERK2
mutant (D321N). A small deletion (aa 1-46) in the N-terminal portion of LC-PTP or Arg to Ala substitutions at aa 41 and 42 resulted in the loss of
ERK
binding activity. These LC-PTP mutants revealed little inhibition of the
ERK
cascade activated by TCR cross-linking. On the other hand, the wild-type LC-PTP did not suppress the phosphorylation of sevenmaker
ERK2
mutant. Thus, the complex formation of LC-PTP with
ERK
is the essential mechanism for the suppression. Taken collectively, these results indicate that LC-PTP suppresses
mitogen-activated protein kinase
directly in vivo.
...
PMID:Direct suppression of TCR-mediated activation of extracellular signal-regulated kinase by leukocyte protein tyrosine phosphatase, a tyrosine-specific phosphatase. 1041 25
Both the nitrite and prostaglandin E2 (PGE2) release caused by lipopolysaccharide (LPS) in J774 macrophages are inhibited by SB 203580, a specific
p38 mitogen-activated protein kinase
(
MAPK
) inhibitor, in a concentration-dependent manner. The 50% inhibitory concentration (IC50) for nitrite and PGE2 responses was 1 microm and 0.5 microm, respectively. Inhibition was marked following simultaneous treatment with SB 203580 and LPS, and was much reduced when SB 203580 was added 6 hr after LPS treatment. In parallel, LPS induction of inducible NO synthase (iNOS) and cyclo-oxygenase-2 (COX-2) proteins and their steady-state levels of mRNA were reduced by SB 203580. LPS activation of nuclear factor-kappa B (NF-kappaB), activator protein-1 (AP-1) and p38
MAPK
was also inhibited by SB 203580. These results suggest a crucial role of p38
MAPK
in regulation of the transcriptional level of endotoxin LPS-induced iNOS and COX-2 protein expression.
...
PMID:Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. 1044 23
The pyridinylimidazole compounds, exemplified by SB 203580, originally were prepared as inflammatory cytokine synthesis inhibitors. Subsequently, the compounds were found to be selective inhibitors for
p38 mitogen-activated protein kinase
(
MAPK
), a member of the
MAPK
family. SB 203580 inhibits the catalytic activity of p38
MAPK
by competitive binding in the ATP pocket. Four homologues of p38
MAPK
have been identified to date, and interestingly, their biochemical properties and their respective sensitivities to the inhibitors are distinct. X-ray crystallographic analysis of p38-inhibitor complexes reinforces the observations made from site-directed mutagenesis studies, thereby providing a molecular basis for understanding the kinase selectivity of these inhibitors. The p38
MAPK
inhibitors are efficacious in several disease models, including inflammation, arthritis and other joint diseases, septic shock, and myocardial injury.
...
PMID:p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials. 1045 14
The superantigen toxic shock syndrome toxin (TSST)-1 can induce tumor necrosis factor (TNF)-alpha expression in T cells and monocytes, through different signaling pathways. We have stimulated peripheral blood mononuclear cells with TSST-1 and found that the major cell producers of TNF-alpha as detected by cytofluorimetry and immunocytochemistry were CD4(+) T lymphocytes. The expression of TNF-alpha by CD4(+) T cells can be inhibited by either, wortmannin (WN) or LY 294002, two phosphatidylinositol 3-kinase (PI 3-K) inhibitors. The inhibitory effect is not transcriptional as WN does not change the mRNA steady state of TNF-alpha at any of the concentrations tested and LY 294002 when preincubated with mononuclear cells at its median inhibitory concentration (IC(50) = 1. 4 microM) significantly inhibited the expression of TNF-alpha but not its mRNA. Immunoprecipitation of pulse-labeled intracellular TNF-alpha showed a specific decrease in the synthesis of this cytokine on cells treated with PI 3-K inhibitors. The
p38 mitogen-activated protein kinase
(
MAPK
) is involved in control of TNF-alpha translation in human macrophages. In T cells, we have found that the p38
MAPK
inhibitor SB 203580 significantly decreased the secretion of TNF-alpha but not its mRNA. In addition, the combined use of WN and SB 203580 had an additive inhibitory effect on secretion of TNF-alpha. Therefore, both PI 3-K and p38
MAPK
signaling pathways control TNF-alpha production in T cells.
...
PMID:Wortmannin inhibits translation of tumor necrosis factor-alpha in superantigen-activated T cells. 1046 69
p38 mitogen-activated protein kinase
(
MAPK
) is activated by T cell receptor engagement. Here we showed that T cell receptor activated p38alpha but not
p38delta
. Inhibition of p38alpha by the specific inhibitor SB 203580 prevented activation-induced cell death in T cells. SB 203580 had no effect on Fas-initiated apoptosis. Instead, SB 203580 preferentially inhibited activation-induced Fas ligand (FasL) expression. The inhibition on FasL expression by SB 203580 was correlated with the suppression on the FasL promoter activation. Overexpression of active
MAPK
kinase 3b, the activator of p38
MAPK
, led to activation of FasL promoter and induction of FasL transcripts in T cells. Stress stimulation of T cells by anisomycin also induced FasL expression in a p38
MAPK
-dependent manner. The induction of FasL expression in nonlymphoid cells such as 293T also required activation of p38
MAPK
. Our results suggest that p38
MAPK
is essential for FasL expression.
...
PMID:p38 mitogen-activated protein kinase is involved in Fas ligand expression. 1046 15
Insulin-like growth factor-I (IGF-I) is known to prevent apoptosis induced by diverse stimuli. The present study examined the effect of IGF-I on the promoter activity of bcl-2, a gene with antiapoptotic function. A luciferase reporter driven by the promoter region of bcl-2 from -1640 to -1287 base pairs upstream of the translation start site containing a cAMP-response element was used in transient transfection assays. Treatment of PC12 cells with IGF-I enhanced the bcl-2 promoter activity by 2.3-fold, which was inhibited significantly (p < 0.01) by SB203580, an inhibitor of
p38 mitogen-activated protein kinase
(
MAPK
). Cotransfection of the bcl-2 promoter with
MAPK
kinase 6 and the beta isozyme of p38
MAPK
resulted in 2-3-fold increase in the reporter activity. The dominant negative form of MAPKAP-K3, a downstream kinase activated by p38
MAPK
, and the dominant negative form of cAMP-response element-binding protein, inhibited the reporter gene activation by IGF-I and p38beta
MAPK
significantly (p < 0.01). IGF-I increased the activity of p38beta
MAPK
introduced into the cells by adenoviral infection. Thus, we have characterized a novel signaling pathway (
MAPK
kinase 6/p38beta
MAPK
/MAPKAP-K3) that defines a transcriptional mechanism for the induction of the antiapoptotic protein Bcl-2 by IGF-I through the nuclear transcription factor cAMP-response element-binding protein in PC12 cells.
...
PMID:Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. 1048 88
The
p38 mitogen-activated protein kinase
(
MAPK
) cascade transduces multiple extracellular signals from cell surface to nucleus and is employed in cellular responses to cellular stresses and apoptotic regulation. The involvement of the p38
MAPK
cascade in opioid- and opioid receptor-like receptor-1 (ORL1) receptor-mediated signal transduction was examined in NG108-15 neuroblastoma x glioma hybrid cells. Stimulation of endogenous delta-opioid receptor (DOR) or ORL1 resulted in activation of p38
MAPK
. It also induced the activation of extracellular signal-regulated kinases (ERKs), another member of the
MAPK
family, with slower kinetics. Activation of p38
MAPK
was abolished by selective antagonists of DOR or ORL1, pretreatment with pertussis toxin, or SB203580, a specific inhibitor of p38
MAPK
. Inhibition of p38
MAPK
had no significant effect on opioid-induced
ERK
activation, indicating that p38
MAPK
activity was not required for
ERK
activation, though its stimulation preceded
ERK
activation. Inhibition of protein kinase A (PKA) strongly diminished p38 activation mediated by DOR or ORL1 but had no significant effect on
ERK
activation, and protein kinase C (PKC) inhibitors potentiated stimulation of p38 while inhibiting activation of ERKs. Taken together, our results provide the first evidence for coupling of DOR and ORL1 to the p38
MAPK
cascade and clearly demonstrate that receptor-mediated activation of p38
MAPK
both involves PKA and is negatively regulated by PKC.
...
PMID:Endogenous delta-opioid and ORL1 receptors couple to phosphorylation and activation of p38 MAPK in NG108-15 cells and this is regulated by protein kinase A and protein kinase C. 1050 Nov 95
<< Previous
1
2
3
4
5
6
7
8
9
10